Digital health funding surged in the first half of 2026, with U.S. companies pulling in $7.4 billion across 244 venture‑capital deals, according to a report from Rock Health.
Large deals dominate the financing field
Nearly half of the capital raised came from mega‑deals—funding rounds of $100 million or more. Those large investments accounted for 45 percent of total money poured into the sector during the period.
The median deal size climbed to $14 million, up from $12 million in the previous year. This rise reflects a concentration of capital in a smaller pool of firms, as investors favor companies with proven traction.
In total, 19 firms secured 20 mega‑deals in the first half of the year, a drop from the 27 such deals recorded in 2025 but still a sizable share of overall financing.
Related: Medicare pay cuts loom for doctors
Sector trends and the role of artificial intelligence
Investment in digital health has rebounded after a dip that followed the pandemic‑driven boom of 2021. The slowdown was linked to inflation and broader macro‑economic headwinds, but funding climbed again in 2025 as interest grew in firms leveraging artificial intelligence.
The analysis shows AI is now so widespread among digital health startups that the firm stopped labeling it as a distinct product category. Nonetheless, AI continues to shape investors’ decisions. The technology lowers barriers to entry, prompting funders to seek founders with deep healthcare expertise who can address buyer concerns.
AI also encourages companies to scale quickly, forging strategic partnerships to build credibility. Buyers are demanding more support as they adopt new tools, and they expect clear returns on investment. “AI has made more tailored implementations possible, but has also flooded buyers with new options, raising expectations for measurable ROI and leaving little appetite for failed deployments,” the report’s authors wrote.
Weight‑management startups attracted the second‑largest share of funding, driven by demand for GLP‑1‑based weight‑loss drugs, while mental‑health platforms remained the top‑funded clinical indication for the seventh consecutive year.
Related: Expiring ACO REACH generates more Medicare savings
For clinicians and patients, the shift toward AI‑driven solutions could mean faster access to personalized care, but it also raises the bar for proving effectiveness. Companies that can demonstrate tangible outcomes are likely to secure the next round of capital.
Acquisitions outpace public offerings
The first half of 2026 saw 115 digital health acquisitions, surpassing the 199 deals recorded in the previous year and far exceeding the 121 transactions in 2024. This activity suggests that exits are increasingly occurring through buyouts rather than IPOs.
Only seven firms went public in 2025, including notable names like Hinge Health and Omada Health. No new IPOs have been announced this year, though wearable‑technology maker Oura is reportedly close to a market debut.
Overall, the data point to a market that is still maturing, with investors gravitating toward larger, AI‑enabled companies and favoring acquisition routes for returns.
